Synonym
Fluphenazine hydrochloride; Anatensol; Lyorodin; Mirenil; Fluphenazine dihydrochloride
IUPAC/Chemical Name
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-, dihydrochloride
InChi Key
MBHNWCYEGXQEIT-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H26F3N3OS.2ClH/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29;;/h1-2,4-7,16,29H,3,8-15H2;2*1H
SMILES Code
OCCN1CCN(CCCN2C3=C(C=CC=C3)SC4=CC=C(C(F)(F)F)C=C24)CC1.[H]Cl.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
510.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015 Feb 5;2:CD000307. doi: 10.1002/14651858.CD000307.pub2. Review. PubMed PMID: 25654768.
2: Tardy M, Huhn M, Engel RR, Leucht S. Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2014 Aug 3;8:CD009230. doi: 10.1002/14651858.CD009230.pub2. Review. PubMed PMID: 25087165.
3: Matar HE, Almerie MQ, Sampson S. Fluphenazine (oral) versus placebo for schizophrenia. Schizophr Bull. 2013 Nov;39(6):1187-8. doi: 10.1093/schbul/sbt140. Epub 2013 Sep 26. Review. PubMed PMID: 24072807; PubMed Central PMCID: PMC3796096.
4: Matar HE, Almerie MQ, Sampson S. Fluphenazine (oral) versus placebo for schizophrenia. Cochrane Database Syst Rev. 2013 Jul 17;7:CD006352. doi: 10.1002/14651858.CD006352.pub2. Review. PubMed PMID: 23861067; PubMed Central PMCID: PMC3997140.
5: Toler SM. Invited review: fluphenazine augments retinal oxidative stress. J Ocul Pharmacol Ther. 2005 Aug;21(4):259-65. Review. PubMed PMID: 16117689.
6: Adams CE, Eisenbruch M. Depot fluphenazine for schizophrenia. Cochrane Database Syst Rev. 2000;(2):CD000307. Review. Update in: Cochrane Database Syst Rev. 2005;(1):CD000307. PubMed PMID: 10796340.
7: Matar HE, Almerie MQ. Oral fluphenazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006352. Review. Update in: Cochrane Database Syst Rev. 2013;7:CD006352. PubMed PMID: 17253589.
8: David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD000307. Review. Update in: Cochrane Database Syst Rev. 2015;2:CD000307. PubMed PMID: 15674872.
9: Glazer WM. Depot fluphenazine: risk/benefit ratio. J Clin Psychiatry. 1984 May;45(5 Pt 2):28-35. Review. PubMed PMID: 6370986.
10: Stevens B. The social value of fluphenazine decanoate. Acta Psychiatr Belg. 1976 Sep-Oct;76(5):792-804. Review. PubMed PMID: 799897.
11: LEDEREROVA E. [FLUPHENAZINE]. Cesk Psychiatr. 1965 Feb;61:63-5. Review. Czech. PubMed PMID: 14345579.
